Home » Stocks » SYNH

Syneos Health, Inc. (SYNH)

Stock Price: $75.50 USD -0.83 (-1.09%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $75.17 -0.33 (-0.44%) Mar 2, 4:19 PM
Market Cap 7.88B
Revenue (ttm) 4.42B
Net Income (ttm) 192.79M
Shares Out 104.17M
EPS (ttm) 1.83
PE Ratio 41.26
Forward PE 18.42
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $75.50
Previous Close $76.33
Change ($) -0.83
Change (%) -1.09%
Day's Open 76.32
Day's Range 74.72 - 77.50
Day's Volume 3,098,760
52-Week Range 30.02 - 81.35

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 day ago

MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization ...

GlobeNewsWire - 1 day ago

MORRISVILLE, N.C., March 01, 2021 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization ...

GlobeNewsWire - 6 days ago

Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review Strategic Partnership Optimizes Integration for EHR Data and Delivers Remote Source Data Review

GlobeNewsWire - 1 week ago

Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy Seasoned Talent to Drive Expansion of Solutions at the Intersection of Value and Policy

Zacks Investment Research - 1 week ago

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

Zacks Investment Research - 1 week ago

Syneos Health (SYNH) delivered earnings and revenue surprises of 0.00% and 0.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 1 week ago

Shares of Syneos Health (NASDAQ:SYNH) remained unaffected after the company reported Q4 results. Quarterly Results Earnings per share rose 7.77% year over year to $1.11, which beat the estimat...

GlobeNewsWire - 1 week ago

Highlights

GlobeNewsWire - 2 weeks ago

Shared Commitment to Change, New Prescriber Realities, Model Evolution and Engagement Transformation Expected to be Critical Drivers Shared Commitment to Change, New Prescriber Realities, Mode...

GlobeNewsWire - 1 month ago

MORRISVILLE, N.C., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its fourth quarter and full ...

GlobeNewsWire - 1 month ago

MORRISVILLE, N.C., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organiz...

Zacks Investment Research - 2 months ago

Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.

GlobeNewsWire - 2 months ago

Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus Acquisition Enhances Company's Decentralized Solutions Offering by Strengthening Patient Focus

Zacks Investment Research - 2 months ago

As of late, it has definitely been a great time to be an investor in Syneos Health (SYNH).

Zacks Investment Research - 2 months ago

Let's see if Syneos Health (SYNH) stock is a good choice for value-oriented investors right now from multiple angles.

Seeking Alpha - 2 months ago

Syneos Health reduced its 2020 guidance but boosted its EBITDA margin guidance.

Business Wire - 2 months ago

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Partners Completes the Sale of Synteract to Syneos Health

GlobeNewsWire - 2 months ago

MORRISVILLE, N.C., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has completed the...

GlobeNewsWire - 2 months ago

Unique Product Development Model Delivers Accelerated Growth

Business Wire - 2 months ago

CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-on...

Other stocks mentioned: VBIV
GlobeNewsWire - 2 months ago

Combination Offers Customers Access to Largest U.S. Oncology Real World Data Source and Best-in-Class Product Development Expertise for Faster, Smarter and More Patient-Centric Clinical Trials...

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...

Zacks Investment Research - 3 months ago

Investors continue to be optimistic about Syneos Health (SYNH) on solid sequential recovery in the Clinical Solutions segment and strategic partnerships.

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization c...

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Larry A...

GlobeNewsWire - 3 months ago

MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organiz...

Zacks Investment Research - 3 months ago

Syneos Health (SYNH) registers sales decline in both its business segments due to slower recovery in reimbursable out-of-pocket expenses across both segments.

GlobeNewsWire - 4 months ago

MORRISVILLE, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organiz...

Seeking Alpha - 4 months ago

Syneos Health, Inc. (SYNH) CEO Alistair Macdonald on Q3 2020 Results - Earnings Call Transcript

Benzinga - 4 months ago

  Shares of Syneos Health (NASDAQ:SYNH) moved higher by 3.2% in pre-market trading after the company reported Q3 results.

Zacks Investment Research - 4 months ago

Syneos Health (SYNH) delivered earnings and revenue surprises of 15.56% and -1.92%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 4 months ago

GREENWICH, Conn.--(BUSINESS WIRE)--Amulet Capital Backed Synteract To Be Acquired by Syneos Health

GlobeNewsWire - 4 months ago

Highlights

GlobeNewsWire - 4 months ago

Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growing Small to Mid-Sized Category Combination Enhances Syneos Health's Industry-Leading Position Across Fast-Growin...

Zacks Investment Research - 4 months ago

Syneos Health (SYNH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 4 months ago

Integrating Intelligence Across Channels, Technologies and Content Achieves Greater Precision, Efficiency and Effectiveness Integrating Intelligence Across Channels, Technologies and Content A...

GlobeNewsWire - 4 months ago

Company Ranks Highest Among Biopharmaceutical Outsourcing Organizations Company Ranks Highest Among Biopharmaceutical Outsourcing Organizations

GlobeNewsWire - 4 months ago

MORRISVILLE, N.C., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it was awarded the S...

GlobeNewsWire - 4 months ago

MORRISVILLE, N.C., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, will release its third quarter 2020 finan...

Zacks Investment Research - 5 months ago

Syneos Health's (SYNH) over 70% of clinical businesses comprise essential therapeutic areas that are experiencing reduced impacts of coronavirus outbreak.

GlobeNewsWire - 5 months ago

MORRISVILLE, N.C., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organizatio...

GlobeNewsWire - 5 months ago

MORRISVILLE, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organizatio...

Investors Business Daily - 5 months ago

A Relative Strength Rating upgrade for Syneos Health shows improving technical performance. Will it continue?

GlobeNewsWire - 5 months ago

MORRISVILLE, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Orga...

Zacks Investment Research - 5 months ago

Syneos Health (SYNH) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 6 months ago

MORRISVILLE, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Orga...

Zacks Investment Research - 6 months ago

Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.

About SYNH

Syneos Health provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist custome... [Read more...]

Industry
Diagnostics & Research
IPO Date
Nov 7, 2014
CEO
Alistair Macdonald
Employees
24,310
Stock Exchange
NASDAQ
Ticker Symbol
SYNH
Full Company Profile

Financial Performance

In 2020, Syneos Health's revenue was $4.42 billion, a decrease of -5.56% compared to the previous year's $4.68 billion. Earnings were $192.79 million, an increase of 46.88%.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for Syneos Health stock is "Buy." The 12-month stock price forecast is 85.60, which is an increase of 13.38% from the latest price.

Price Target
$85.60
(13.38% upside)
Analyst Consensus: Buy